Navigation Links
Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug
Date:11/5/2007

CHAPEL HILL, N.C., and VALAIS, Switzerland, Nov. 5 /PRNewswire/ -- Lantibio, Inc. and TRB Chemedica announced today the signing of a licensing agreement with a subsidiary of Alcon, Inc. (NYSE: ACL) for the US development, marketing, and manufacture of a Dry Eye Syndrome product. The product consists of a TRB patented formulation containing sodium hyaluronate and is currently being studied in the US under an IND by a subsidiary of Lantibio. An ongoing multi-center Phase III pivotal study is being conducted under the FDA's Special Protocol Assessment program. Lantibio expects to file an NDA in 2008 for the product as a treatment for Dry Eye Syndrome.

In Dry Eye Syndrome, it is hypothesized that the product, administered via ocular instillation will hydrate the surface of the eye preventing dryness and long-term ocular injury. Sodium hyaluronate is a known natural molecule with viscoelastic properties that in preparation with specific ions and chelators, lubricates the eye and hydrates the ocular surface.

Under the terms of the agreement, Lantibio will conduct the development program and filing of the NDA, while Alcon will assume responsibility for subsequent marketing, sales and manufacturing for the US market. Terms of the agreement include up-front and development milestone payments, as well as royalties to be paid to Lantibio and TRB by Alcon on sales of the approved product.

"We believe this product will bring significant relief to patients with Dry Eye Syndrome and look forward to completing our clinical study and to filing an NDA with the FDA for approval in the US," said Andrew Schiermeier, Ph.D., Chief Executive Officer of Lantibio, Inc. "We are delighted by this agreement, and could not hope fo
'/>"/>

SOURCE Lantibio, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/16/2014)... The “Fluid Management & Visualization Systems ... market with an analysis and forecast of value ... fluid warming and waste management. Along with this, ... systems by applications and regions are also discussed ... at $19,285.5 million in 2013 and is expected ...
(Date:11/15/2014)... The redesigned ActiGraph Link expands upon ... measurement platform with a rich feature set that ... new channels of sensor data captured by a ... Smart technology, the ActiGraph Link supports wireless heart ... ActiGraph’s cloud-based Study Admin platform, giving academic and ...
(Date:11/15/2014)... The "Operating Room Management Market by Product ... Preoperative, operating room Scheduling), by Component (Software, Services), ... to 2019.” defines and segments the operating room ... value by product, such as data management, anesthesia, ... and volumes of operating room management market by ...
(Date:11/15/2014)... 2014 Algenol Biofuels will present at CleanEquity Monaco ... of Monaco . Logo - ... annual invitation-only event hosted by Innovator Capital, the ... partners and sponsors include Prince Albert II of ... University, PR Newswire, the Monte-Carlo SBM, Oceanographic Museum of ...
Breaking Biology Technology:Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 2Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 3Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 4ActiGraph Launches GT9X Link Activity Monitor 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 3Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 4Algenol Biofuels Selected to Present at CleanEquity Monaco 2015 2
... Nov. 7 Interleukin Genetics,Inc. (Amex: ILI ), ... and genetic tests for sale to the,emerging personalized health ... 30, 2007. The Company recorded revenue of $2.6 ... million for third quarter ended September 30,2006, a 92% ...
... Function and Tissue Preservation ... in Spinal Cord Injury Model, SAN DIEGO, Nov. ... today the presentation of preclinical data from,its ZFP Therapeutic(TM) ... Meeting of the Society for Neuroscience. A statistically,significant effect ...
... Nov. 7 SyntheMed, Inc. (OTC,Bulletin Board: SYMD), ... of anti-adhesion, tissue repair and drug delivery,products, announced ... registration,statement with the Securities and Exchange Commission (SEC) ... SyntheMed to sell, from time to,time, up to ...
Cached Biology Technology:Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 2Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 3Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 4Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 5Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 6Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting 2Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting 3Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting 4Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting 5SyntheMed Files Universal Shelf Registration 2
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
(Date:11/4/2014)... Nov. 4, 2014   Neurotechnology , a ... that the latest version of its fingerprint matching ... Ongoing MINEX evaluation organized by NIST. The ... using the INCITS 378 fingerprint standard template format. ... public tenders in the United States ...
(Date:11/3/2014)... published in this month,s Proceedings of the ... a recently discovered communication molecule of the body,s immune ... to limit inflammation and the current study reports its ... ability of the immune system to recognize and target ... effect on the immune system now allows us to ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... who study HIV are facing a troubling consequence of their ... patients almost normal life expectancy. However, those same drugs will ... form that eludes current treatments. With a new $3.4 ... of Missouri is leading a team of researchers who want ...
... in the eye often are fatal. Now, scientists at Washington ... identified a mutated gene in melanoma tumors of the eye ... is published in the advance online edition of Nature ... SF3B1," says senior author Anne Bowcock, PhD, professor of genetics. ...
... TEMPE, Ariz.---Arizona State University,s Biodesign Institute has announced ... enters the next phase of a multi-million-dollar, multi-institutional ... rapidly assess an individual,s exposure to radiation in ... project enters a $9.33 million contract option as ...
Cached Biology News:Researchers attack HIV's final defenses before drug-resistant mutations emerge 2Researchers attack HIV's final defenses before drug-resistant mutations emerge 3Gene in eye melanomas linked to good prognosis 2ASU partners with Life Technologies on US DHHS funded project to rapidly assess radiation dose 2
... The CHEMICON® CaspaTag™ Caspase-9 Pan-Caspase In ... assay for detection of active caspases in ... research use only. Not for use in ... Situ Caspase Detection Kits use a novel ...
... The transformation of Saccharomyces cerevisiae, as ... routine procedure in many molecular biology laboratories. ... high efficiencies with plasmid and linear DNAs ... has made routine plasmid transformations and library ...
... a fluorescein-conjugated jetSI-ENDO (excitation ... 520 nm), the powerful siRNA ... used to determine the transfection ... delivery and trafficking of siRNAs. ...
... for high efficiency siRNA delivery ... reagent proven to work effectively ... cell types. Results in silencing ... target gene expression. One step, ...
Biology Products: